Outrage of the Month: Congressional Probe Confirms Inappropriate FDA-Biogen Collaboration on Alzheimer’s Disease Drug February 1, 2023
Letters, Testimony & Filings Letter to the FDA Urging Postponement of the Approval Decision Regarding Lecanemab for Treatment of Alzheimer’s Disease January 4, 2023
Outrage of the Month: Lifesaving Insulin Remains Unaffordable for Too Many U.S. Patients January 1, 2023
Letters, Testimony & Filings Letter to the FDA Opposing Approval of Daprodustat and Other Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors December 14, 2022
Letters, Testimony & Filings Testimony Before the FDA’s Cardiovascular and Renal Drugs Advisory Committee Regarding Omecamtiv Mecarbil For the Treatment of Heart Failure December 13, 2022
Outrage of the Month: Congress Reauthorizes FDA-Corrupting User Fees for Five More Years December 1, 2022